Endocrinologists weigh a possible vision-loss risk from GLP-1 drugs against their proven benefits

GLP-1 receptor agonists are now central to managing type 2 diabetes and obesity, so any safety signal affects a very large patient population. One signal that has drawn attention is non-arteritic anterior ischemic optic neuropathy (NAION), a cause of sudden vision loss from impaired blood supply to the front of the optic nerve.

This article, written for endocrinologists, is a narrative review of the current research on NAION risk with GLP-1 receptor agonist use in people with type 2 diabetes and obesity. It also analyzes patient factors that might increase susceptibility and identifies priorities for future research to guide prescribing.

The studies supporting an association are retrospective cohorts. They report hazard ratios ranging from 2.19 to 7.74 when people exposed to GLP-1 receptor agonists are compared with unexposed groups. That range is wide, which points to considerable variability and uncertainty in the size of any effect.

The authors conclude that the evidence suggests a possible association between starting a GLP-1 receptor agonist and NAION. They stress that absolute risk remains low and must be balanced against the known substantial benefits of these drugs. They propose that optic disc parameters, blood pressure changes, degree of weight loss, and improvement in glycemic control could help identify patients at higher risk, but these ideas remain untested.

Several caveats apply. This summary is based only on the abstract, so study-level details, such as comparator groups, confounder adjustment, and individual drug differences, are unavailable. Retrospective cohort data cannot establish causation, and underlying diabetes or obesity may itself influence NAION risk. Until prospective data clarify who is most vulnerable, clinicians must rely on individualized judgment and patient counseling.